MYC and erythroleukemia: Leukemic cells expressed high levels of Myc but did not harbor any gross chromosomal or Trp53 alterations.53 Although the erythroleukemia phenotype does not match the human disease associated with this fusion, these transgenic mice provided an in vivo platform to study strategies for therapeutic targeting of EWS-FLI1-driven tumors.97 Notably, several compounds were found that inhibit Fli-1 transcriptional activities and impaired EWS-FLI-1-driven erythroleukemia in mice.